专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20180125876A1 Methods and Pharmaceutical Composition for Modulation Polarization and Activation of Macrophages 审中-公开
公开(公告)号：US20180125876A1
公开(公告)日：2018-05-10
申请号：US15574868
申请日：2016-05-20
申请人： INSERM (Institut National de la Sante et de la Recherche Medicale) , Université Paris sud , Institut Gustave Roussy , Institut Pasteur
发明人： Jean-Luc Perfettini , Audrey Paoletti , Marie-Lise Gougeon , Guido Kroemer , Mauro Piacentini
IPC分类号： A61K31/7072 , A61K31/7084 , A61K31/7076 , A61K31/7034 , A61K38/17 , A61K48/00 , A61P35/00 , A61P31/00 , A61P37/00 , A61P29/00
CPC分类号： A61K31/7072 , A61K31/7034 , A61K31/7076 , A61K31/7084 , A61K38/177 , A61K48/00 , A61P29/00 , A61P31/00 , A61P35/00 , A61P37/00 , Y02A50/385 , Y02A50/401 , Y02A50/409 , Y02A50/411 , Y02A50/473 , Y02A50/478
摘要： The present invention relates to methods and pharmaceutical composition for modulation polarization and activation of macrophages. In particular, the present invention relates to methods for modulating macrophage M1/M2 polarization in a subject in need thereof comprising administering to the subject a therapeutically effective amount of P2Y2 receptor agonists or antagonists.

2. 发明授权

US09938528B2 Methods and pharmaceutical compositions for treating human immunodeficiency virus type 1 (HIV-1) infections 有权
公开(公告)号：US09938528B2
公开(公告)日：2018-04-10
申请号：US15534321
申请日：2015-12-10
申请人： INSERM (Institut National de la Sante et de la Recherche Medicale) , Universite Paris-Sud , Institut Gustave Roussy , Universite Paris Descartes , Universite Pierre et Marie Curie (Paris 6) , Institut Pasteur , Istituto Nazionale per Le Malattie Infettive IRCCS Lazzaro Spallanzani , Assistance Publique-Hopitaux de Paris (APHP)
发明人： Guido Kroemer , Jean-Luc Perfettini , Marie-Lise Gougeon , Awatef Allouch , Mauro Piacentini
IPC分类号： C12N15/11 , C12N15/113 , A61K45/06 , A61K31/683 , A61K31/5517 , A61K31/165 , A61K31/395 , A61K31/17 , A61K31/713 , C12Q1/18
CPC分类号： C12N15/113 , A61K31/165 , A61K31/17 , A61K31/395 , A61K31/5517 , A61K31/683 , A61K31/7088 , A61K31/713 , A61K45/06 , C12N15/1132 , C12N2310/14 , C12N2320/31 , C12Q1/18 , A61K2300/00
摘要： The present invention provides methods and pharmaceutical compositions for treating human immunodeficiency virus type 1 (HIV-1) infections. In particular, the present invention relates to a method for treating HIV-1 infection in a subject in need thereof comprising administering the subject with a therapeutically effective amount of an inhibitor of SGT1 activity or expression.

3. 发明授权

US11040052B2 Methods and pharmaceutical compositions for modulating autophagy in a subject in need thereof 有权
公开(公告)号：US11040052B2
公开(公告)日：2021-06-22
申请号：US16011686
申请日：2018-06-19
申请人： INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE)
发明人： Guido Kroemer , Guillermo Marino , Federico Pietrocola
IPC分类号： A61K31/7076 , A61K31/225 , A61K31/235 , A61K31/4155 , A61K31/7008 , A61K31/4458 , A61K45/06 , A61K31/385 , A61K31/22 , A61K31/216 , A61K31/194 , A61K31/19 , A61K31/405
摘要： The present invention provides novel methods for the modulation of autophagy and the treatment of autophagy-related diseases, including cancer, neurodegenerative diseases, liver diseases, muscle diseases and pancreatitis.

4. 发明申请

US20170363613A1 SIMULTANEOUS DETECTION OF CANNIBALISM AND SENESCENCE AS PROGNOSTIC MARKER FOR CANCER 审中-公开
公开(公告)号：US20170363613A1
公开(公告)日：2017-12-21
申请号：US15642273
申请日：2017-07-05
申请人： Institut Gustave-Roussy
发明人： JEAN-LUC PERFETTINI , Guido Kroemer , Eric Deutsch
IPC分类号： G01N33/50 , G01N33/68 , G01N33/574 , C12Q1/68 , C12N15/113 , G01N33/566
CPC分类号： G01N33/5011 , C12N15/113 , C12N15/1135 , C12N2310/14 , C12N2310/141 , C12Q1/6881 , C12Q1/6886 , C12Q2600/106 , C12Q2600/136 , C12Q2600/156 , G01N33/566 , G01N33/574 , G01N33/57496 , G01N33/6872 , G01N2800/52
摘要： The present inventors show that cannibal cells can undergo senescence after entosis in vivo and that the tumor suppressive protein p53 act as a repressor of this phenomenon. They therefore propose new tools to study the molecular pathways involved in the cannibalism process, for example by measuring the expression levels of p53 or splice variants thereof (such as Δ133TP53, TP53β, TP53γ or Δ40TP53), the release of extracellular ATP or purinergic P2Y2 receptor activity. The present inventors also demonstrated that the detection of senescent cannibal cells in breast adenocarcinoma obtained from patients treated with neo-adjuvant therapy positively correlates with good patient's response to treatment. Altogether, these results provide the first evidence that detection of cellular cannibalism and senescence simultaneously in tumors helps for the diagnosis of disease outcomes and for the prediction of treatment efficiency against cancer diseases.

5. 发明授权

US09726661B2 Simultaneous detection of cannibalism and senescence as prognostic marker for cancer 有权
公开(公告)号：US09726661B2
公开(公告)日：2017-08-08
申请号：US14412571
申请日：2013-07-08
申请人： INSTITUT GUSTAVE-ROUSSY
发明人： Jean-Luc Perfettini , Guido Kroemer , Eric Deutsch
IPC分类号： C12N15/11 , G01N33/50 , C12Q1/68 , G01N33/574 , C12N15/113 , G01N33/566 , G01N33/68
CPC分类号： G01N33/5011 , C12N15/113 , C12N15/1135 , C12N2310/14 , C12N2310/141 , C12Q1/6881 , C12Q1/6886 , C12Q2600/106 , C12Q2600/136 , C12Q2600/156 , G01N33/566 , G01N33/574 , G01N33/57496 , G01N33/6872 , G01N2800/52
摘要： The present inventors show that cannibal cells can undergo senescence after entosis in vivo and that the tumor suppressive protein p53 act as a repressor of this phenomenon. They therefore propose new tools to study the molecular pathways involved in the cannibalism process, for example by measuring the expression levels of p53 or splice variants thereof (such as Δ133TP53, TP53β, TP53γ or Δ40TP53), the release of extracellular ATP or purinergic P2Y2 receptor activity. The present inventors also demonstrated that the detection of senescent cannibal cells in breast adenocarcinoma obtained from patients treated with neo-adjuvant therapy positively correlates with good patient's response to treatment. Altogether, these results provide the first evidence that detection of cellular cannibalism and senescence simultaneously in tumors helps for the diagnosis of disease outcomes and for the prediction of treatment efficiency against cancer diseases.

6. 发明授权

US10969380B2 Simultaneous detection of cannibalism and senescence as prognostic marker for cancer 有权
公开(公告)号：US10969380B2
公开(公告)日：2021-04-06
申请号：US15642273
申请日：2017-07-05
申请人： Institut Gustave-Roussy
发明人： Jean-Luc Perfettini , Guido Kroemer , Eric Deutsch
IPC分类号： G01N33/50 , G01N33/566 , G01N33/68 , C12N15/113 , C12Q1/6881 , C12Q1/6886 , G01N33/574
摘要： The present inventors show that cannibal cells can undergo senescence after entosis in vivo and that the tumor suppressive protein p53 act as a repressor of this phenomenon. They therefore propose new tools to study the molecular pathways involved in the cannibalism process, for example by measuring the expression levels of p53 or splice variants thereof (such as Δ133TP53, TP53β, TP53γ or Δ40TP53), the release of extracellular ATP or purinergic P2Y2 receptor activity. The present inventors also demonstrated that the detection of senescent cannibal cells in breast adenocarcinoma obtained from patients treated with neo-adjuvant therapy positively correlates with good patient's response to treatment. Altogether, these results provide the first evidence that detection of cellular cannibalism and senescence simultaneously in tumors helps for the diagnosis of disease outcomes and for the prediction of treatment efficiency against cancer diseases.

7. 发明申请

US20150185202A1 SIMULTANEOUS DETECTION OF CANNIBALISM AND SENESCENCE AS PROGNOSTIC MARKER FOR CANCER 有权
标题翻译：同时检测可卡因和感冒作为癌症的临床标记
公开(公告)号：US20150185202A1
公开(公告)日：2015-07-02
申请号：US14412571
申请日：2013-07-08
申请人： INSTITUT GUSTAVE-ROUSSY
发明人： Jean-Luc Perfettini , Guido Kroemer , Eric Deutsch
IPC分类号： G01N33/50 , C12N15/113
CPC分类号： G01N33/5011 , C12N15/113 , C12N15/1135 , C12N2310/14 , C12N2310/141 , C12Q1/6881 , C12Q1/6886 , C12Q2600/106 , C12Q2600/136 , C12Q2600/156 , G01N33/566 , G01N33/574 , G01N33/57496 , G01N33/6872 , G01N2800/52
摘要： The present inventors show that cannibal cells can undergo senescence after entosis in vivo and that the tumor suppressive protein p53 act as a repressor of this phenomenon. They therefore propose new tools to study the molecular pathways involved in the cannibalism process, for example by measuring the expression levels of p53 or splice variants thereof (such as Δ133TP53, TP53β, TP53γ or Δ40TP53), the release of extracellular ATP or purinergic P2Y2 receptor activity. The present inventors also demonstrated that the detection of senescent cannibal cells in breast adenocarcinoma obtained from patients treated with neo-adjuvant therapy positively correlates with good patient's response to treatment. Altogether, these results provide the first evidence that detection of cellular cannibalism and senescence simultaneously in tumors helps for the diagnosis of disease outcomes and for the prediction of treatment efficiency against cancer diseases.
摘要翻译：本发明人表明，食人族细胞在体内诱导后可以衰老，并且肿瘤抑制蛋白p53作为该现象的阻遏物。因此，他们提出了新的工具来研究自相残疾过程中涉及的分子途径，例如通过测量p53或其剪接变体（例如＆Dgr; 133TP53，TP53＆bgr;TP53γ或＆Dgr; 40TP53）的表达水平，细胞外释放 ATP或嘌呤能P2Y2受体活性。本发明人还证实，从用新辅助治疗的患者获得的乳腺腺癌中衰老食饵细胞的检测与良好的患者对治疗的反应正相关。总之，这些结果提供了第一个证据，即在肿瘤中同时检测细胞嗜食性和衰老有助于诊断疾病结果，并预测治疗效果对抗癌症疾病。

8. 发明授权

US08865653B2 Method of treatment for immunogenic treatment resistant cancer 有权
标题翻译：免疫原性治疗耐药性癌症的治疗方法
公开(公告)号：US08865653B2
公开(公告)日：2014-10-21
申请号：US13772944
申请日：2013-02-21
申请人： Institut Gustave Roussy
发明人： Laurence Zitvogel , Guido Kroemer
IPC分类号： A61P35/00 , A61K39/395 , C12Q1/68 , A61N5/10
CPC分类号： C12Q1/6886 , A61N5/10 , A61N2005/1098 , C12Q2600/106 , C12Q2600/158
摘要： The present invention relates to the fields of genetics, immunology and medicine. The present invention more specifically relates to in vitro or ex vivo methods for determining the susceptibility to a cancer treatment of a subject having a tumor. These methods comprise a step of determining the ability of the treatment, of the subject and/or of the tumor to induce an anticancer immune response, the inability of at least one of the treatment, the subject and the tumor to induce an anticancer immune response being indicative of a resistance of the subject to the therapeutic treatment of cancer. Inventors in particular identify genes specific of a human subject or of cancerous cells which can be used to predict or assess the sensitivity of a subject to a treatment of cancer. The invention also relates to particular compounds capable of activating or enhancing the immune system of a particular subject, when the subject is exposed to a therapeutic treatment of cancer or before such an exposition. It further relates to uses of such compounds, in particular to prepare a pharmaceutical composition to allow or improve the efficiency of a therapy of cancer in a subject in need thereof. The present invention in addition provides kits, methods for selecting a compound of interest, as well as pharmaceutical compositions and uses thereof.
摘要翻译：本发明涉及遗传学，免疫学和医学领域。本发明更具体地涉及用于确定具有肿瘤的受试者的癌症治疗的易感性的体外或离体方法。这些方法包括确定治疗，受试者和/或肿瘤诱导抗癌免疫应答的能力的步骤，至少一种治疗，受试者和肿瘤的不能诱导抗癌免疫应答指示受试者对癌症的治疗性治疗的抗性。发明人特别地鉴定可以用于预测或评估受试者对癌症治疗的敏感性的人受试者或癌细胞特异性的基因。本发明还涉及能够激活或增强特定受试者的免疫系统的特定化合物，当受试者暴露于癌症的治疗性治疗或在这种暴露之前。它还涉及这些化合物的用途，特别是制备药物组合物以允许或提高有需要的受试者的癌症治疗效率。本发明另外提供试剂盒，选择目标化合物的方法，以及药物组合物及其用途。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式